Affordable Access

Publisher Website

Angiogenesis inhibitor or aggressiveness marker? The function of endostatin in cancer through electrochemical biosensing.

Authors
  • Tejerina-Miranda, Sandra1
  • Pedrero, María1
  • Blázquez-García, Marina1
  • Serafín, Verónica1
  • Montero-Calle, Ana2
  • Garranzo-Asensio, Maria2
  • Julio Reviejo, A1
  • Pingarrón, José M1
  • Barderas, Rodrigo2
  • Campuzano, Susana3
  • 1 Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, 28040 Madrid, Spain. , (Spain)
  • 2 Chronic Disease Programme, UFIEC, Institute of Health Carlos III, Majadahonda, 28220 Madrid, Spain. , (Spain)
  • 3 Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, 28040 Madrid, Spain. Electronic address: [email protected]. , (Spain)
Type
Published Article
Journal
Bioelectrochemistry (Amsterdam, Netherlands)
Publication Date
Feb 01, 2024
Volume
155
Pages
108571–108571
Identifiers
DOI: 10.1016/j.bioelechem.2023.108571
PMID: 37717337
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

This work reports the first electrochemical bioplatform developed for the determination of human endostatin (HE), a biomarker with recognized antiangiogenic potential whose elevated circulating levels have also been associated with the development of aggressive cancers. The developed electroanalytical biotool combines the benefits of using magnetic microparticles for the implementation of sandwich immunoassays and amperometric transduction on disposable carbon electrodes. A limit of detection (LOD) of 34.1 pg mL-1 for HE standards and a selectivity suitable for its foray into the clinical oncology area, are demonstrated. The determination of HE in clinical samples such as lysates and secretomes of colorectal cancer (CRC) cells, plasma, and tissue samples from patients with CRC in different stages, has been faced with satisfactory results showing the ability for discriminating the metastatic capabilities of cells and for identifying and staging CRC patients. The developed bioplatform allows precise quantitative determinations, requiring minimal pre-treatments and sample amounts in only 75 min. In addition, due to the instrumentation and the type of substrates used in the detection step, the biotool is compatible with implementation in multiplexed and/or point-of-need devices, features in which this bioplatform is advantageous with respect to the enzyme linked immunosorbent assay (ELISA) or immunoblotting technologies. Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times